Heidelberg Pharma reports on the results of the Annual General Meeting 2024

EQS-News: Heidelberg Pharma AG / Key word(s): AGM/EGM
Heidelberg Pharma reports on the results of the Annual General Meeting 2024

21.06.2024 / 11:16 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PRESS RELEASE

Heidelberg Pharma reports on the results of the Annual General Meeting 2024

Ladenburg, Germany, 21 June 2024 - Heidelberg Pharma AG (FSE: HPHA)
announced that the company's shareholders approved the following proposed
resolutions of the management with a large majority (between 98,35% and
99,99%) at yesterday's ordinary virtual Annual General Meeting:

  * Discharge of the members of the Management Board and the Supervisory
    Board for the fiscal year 2022/2023

* Appointment of the auditors and group auditors for fiscal year 2023/2024

  * Cancellation of Authorised Capital 2022/I and creation of new Authorised
    Capital 2024/I with the option to exclude statutory subscription rights
    and corresponding amendments to the Articles of Association

* Approval of the remuneration report

Attendance (incl. postal votes cast) at the Annual General Meeting 2024
corresponded to 83,18% of the current capital stock.

For more information on the Annual General Meeting, including the voting
results, please visit: https://heidelberg-pharma.com/de/hv

About Heidelberg Pharma

Heidelberg Pharma develops novel drugs based on its ADC technologies for the
targeted and highly effective treatment of cancer. ADCs are antibody-drug
conjugates that combine the specificity of antibodies with the efficacy of
toxins to fight cancer. Selected antibodies are loaded with cytotoxic
compounds, the so-called payloads, that are transported into diseased cells.
Inside the cells, the toxins then unleash their effect and kill the diseased
cells.

Heidelberg Pharma is the first company to use the mushroom toxin Amanitin in
cancer therapy by exploiting the toxin's biological mechanism of action with
its innovative ATAC technology as a new therapeutic modality. It offers the
opportunity to overcome resistance of cancer cells against therapeutic
agents currently used and to eliminate dormant tumor cells, which typically
survive current therapies and are responsible for tumor relapse and
metastasis. This could lead to significant advances in cancer therapy - even
for patients who no longer respond to any other treatment. The most advanced
product candidate HDP-101 is a BCMA-ATAC for the indication multiple
myeloma, which is currently in clinical development.

In addition to Amanitin, alternative payloads also expand the ADC platform
technologies of Heidelberg Pharma to develop targeted and highly effective
ADCs for the treatment of a variety of malignant hematologic and solid
tumors.

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg,
Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 /
WKN A11QVV / Symbol HPHA. More information is available at
www.heidelberg-pharma.com.

ATAC® is a registered trademark of Heidelberg Pharma Research GmbH.

   Contact Heidelberg Pharma AG Sylvia       IR/PR-Support MC Services AG
             Wimmer Director Corporate       Katja Arnold (CIRO) Managing
     Communications Tel.: +49 89 41 31    Director & Partner Tel.: +49 89
                         38-29 E-mail:                 210 228-40 E-mail:
             (1)investors@hdpharma.com     (1)katja.arnold@mc-services.eu
          Gregor-Mendel-Str. 22, 68526                                 1.
                         Ladenburg  1.    mailto:katja.arnold@mc-services
         mailto:investors@hdpharma.com                                .eu

This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as "estimates", "believes", "expects",
"may", "will" "should" "future", "potential" or similar expressions or by a
general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial condition, performance, or achievements, or industry results, to
be materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to place
undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.


---------------------------------------------------------------------------

21.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Heidelberg Pharma AG
                   Gregor-Mendel-Str. 22
                   68526 Ladenburg
                   Germany
   Phone:          +49 (0)89 41 31 38 - 0
   Fax:            +49 (0)89 41 31 38 - 99
   E-mail:         investors@hdpharma.com
   Internet:       www.heidelberg-pharma.com
   ISIN:           DE000A11QVV0
   WKN:            A11QVV
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Munich, Stuttgart, Tradegate Exchange
   EQS News ID:    1930755

End of News EQS News Service
---------------------------------------------------------------------------

1930755 21.06.2024 CET/CEST